Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA

202433 citationsJournal Articlegold Open Access

Authors

Aaron A. King · Baptist Health System

Xi Tan · Novo Nordisk (United States)

Neil Dhopeshwarkar · TriNetX (United States)

Rhonda L. Bohn · Our Bodies Ourselves

Katherine Dea · Cambridge Econometrics (United Kingdom)

Charles E. Leonard · University of Pennsylvania

Adam de Havenon

Abstract

Use of GLP-1 RAs/SGLT2is in patients with T2D and ASCVD has increased in recent years in the USA, but remains suboptimal given the prevalence of ASCVD and its high morbidity and mortality.

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMJ Open Diabetes Research & Care

Volume 12, Issue 5, pp. e004431-e004431

DOI: 10.1136/bmjdrc-2024-004431

Field-Weighted Citation Impact: 11.50